Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Conditions
Interventions
Dalantercept
Laboratory Biomarker Analysis
Locations
30
United States
UCSF Medical Center-Mount Zion
San Francisco, California, United States
Beebe Medical Center
Lewes, Delaware, United States
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Florida Hospital Orlando
Orlando, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Start Date
September 1, 2012
Primary Completion Date
January 1, 2016
Completion Date
January 1, 2016
Last Updated
March 13, 2018
NCT06399757
NCT07077876
NCT03660826
NCT03586661
NCT05824481
NCT00977574
Lead Sponsor
Gynecologic Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions